At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 29, 2026 at 19:06 ET
Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 years old, the seventh FDA approval for ZORYVE in four years. This addresses a significant treatment gap in pediatric psoriasis, where limited steroid-free options existed for young children. The approval is based on a Phase 2 MUSE study and long-term extension data showing safety and efficacy consistent with adult/adolescent trials.
- FDA approved sNDA for ZORYVE cream 0.3% to treat plaque psoriasis in children down to age 2, including intertriginous areas
- Seventh FDA approval for ZORYVE in four years; first once-daily steroid-free topical approved for ages 2+ with plaque psoriasis
- Approval based on 4-week MUSE study (ARQ-151-216) in children ages 2-5 and 24-week open-label extension (ARQ-151-306)
- ZORYVE cream 0.3% already approved for adults and children down to age 6; this expansion adds ages 2-5
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access